AveXis Inc (NASDAQ:AVXS) issued its earnings results on Thursday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.15. During the same period last year, the business earned ($1.82) earnings per share.
Shares of AveXis (NASDAQ:AVXS) traded down 4.82% during midday trading on Friday, hitting $69.47. The stock had a trading volume of 611,829 shares. AveXis has a 1-year low of $20.51 and a 1-year high of $85.98. The firm’s 50-day moving average price is $65.38 and its 200-day moving average price is $54.55. The stock’s market cap is $1.93 billion.
COPYRIGHT VIOLATION NOTICE: “AveXis Inc (AVXS) Announces Earnings Results” was first reported by Web Breaking News and is the sole property of of Web Breaking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at http://www.webbreakingnews.com/2017/03/20/avexis-inc-avxs-announces-earnings-results.html.
A number of equities analysts have issued reports on the company. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 target price on shares of AveXis in a report on Friday, March 17th. Jefferies Group LLC upped their target price on AveXis from $79.00 to $92.00 and gave the stock a “buy” rating in a report on Friday, March 17th. Goldman Sachs Group Inc upped their target price on AveXis from $91.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, March 17th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $95.00 target price (up previously from $85.00) on shares of AveXis in a report on Friday, March 17th. Finally, Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a report on Tuesday, February 14th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. AveXis currently has a consensus rating of “Buy” and a consensus price target of $85.33.
In other news, VP Sukumar Nagendran sold 1,781 shares of the firm’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $76.13, for a total value of $135,587.53. Following the completion of the transaction, the vice president now directly owns 1,781 shares of the company’s stock, valued at $135,587.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Large investors have recently bought and sold shares of the stock. Opus Point Partners Management LLC acquired a new stake in AveXis during the fourth quarter valued at about $239,000. Pacad Investment Ltd. acquired a new stake in AveXis during the fourth quarter valued at about $277,000. A.R.T. Advisors LLC raised its stake in AveXis by 68.8% in the fourth quarter. A.R.T. Advisors LLC now owns 10,800 shares of the company’s stock valued at $515,000 after buying an additional 4,400 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in AveXis during the fourth quarter valued at about $640,000. Finally, Norges Bank acquired a new stake in AveXis during the fourth quarter valued at about $1,193,000. 68.31% of the stock is owned by institutional investors.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.